Opthea Limited (OPTEY)
| Market Cap | 15.73M -94.8% |
| Revenue (ttm) | -13.42K -43.3% |
| Net Income | 198.09M |
| EPS | 0.15 |
| Shares Out | n/a |
| PE Ratio | 0.08 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 460,598 |
| Open | 0.0250 |
| Previous Close | 0.0300 |
| Day's Range | 0.0250 - 0.0250 |
| 52-Week Range | 0.0017 - 3.1700 |
| Beta | 1.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 5, 2026 |
About Opthea
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea... [Read more]
Financial Performance
In fiscal year 2025, Opthea's revenue was 222,694, a decrease of -43.29% compared to the previous year's 392,686. Losses were -248.31 million, -24.78% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Opthea Quarterly report: H1 2026
Opthea has published its H1 2026 quarterly earnings report on February 28, 2026.
Opthea Transcript: AGM 2025
The AGM covered director re-elections, adoption of the remuneration report, and approval of option grants, with all resolutions put to a poll and no questions raised by shareholders. Voting results will be published post-meeting.
Opthea Earnings release: Q1 2026
Opthea released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
Opthea Annual report: H2 2025
Opthea has published its H2 2025 annual report on September 22, 2025.
Opthea Annual report: H2 2025
Opthea has published its H2 2025 annual report on September 22, 2025.
Opthea Transcript: Investor Update
Phase III trials failed to show efficacy for sozinibercept in wet AMD, leading to program termination and a settlement with investors that leaves the company with $20 million cash and no debt. A strategic review is underway to explore internal and external opportunities, with updates expected later this year.
Opthea Press release: Investor Update
Opthea issued a press release on August 19, 2025, disclosing material business information to investors.
Opthea Slides: Investor Update
Opthea has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2025.
Opthea Provides Corporate Update
Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to contin...
Opthea Earnings release: Q4 2025
Opthea released its Q4 2025 earnings on July 29, 2025, summarizing the period's financial results.
Opthea terminates COAST trial, announces ShORe trial misses endpoint
Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its second Phase 3 trial ShORe in patients with wet…
Opthea Announces Decision to Discontinue Wet AMD Trials
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Opthea downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Opthea (OPT) to Perform from Outperform.
Opthea downgraded to Market Perform from Outperform at Leerink
Leerink analyst Marc Goodman downgraded Opthea (OPT) to Market Perform from Outperform.
Opthea cut to Market Perform at Leerink on failed sozinibercept trial
Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company announcing that its Phase 3 COAST trial…
Opthea double downgraded to Underperform from Buy at Jefferies
Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8, after the company announced that its Eylea combo trial failed to meet…
Opthea downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield downgraded Opthea (OPT) to Neutral from Buy with a price target of $2, down from $12 after the Phase 3 COAST Eylea combo trial failed…
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors
Opthea (OPT) announced results from its global Phase 3 clinical trial COAST in patients with wet AMD. The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally…
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
Opthea Press release: Study Result
Opthea issued a press release on March 23, 2025, disclosing material business information to investors.
Opthea Ltd (ADR) trading halted, news pending
10:07 EDT Opthea (OPT) Ltd (ADR) trading halted, news pending
Opthea announces Phase 2b Wet AMD publication
Opthea (OPT) announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina. The paper entitled “Sozinibercept Combination Therapy ...
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea reports 1H adjusted EPS ($5.73) vs. ($14.25) last year
Reports 1H revenue $149,000 vs. $202,000 last year. “Opthea (OPT) is making significant progress on its mission to deliver superior vision to patients with wet AMD enabling them to live…
Opthea announces anticipated milestones
Phase 3 topline results from COAST, expected in early Q2 CY2025; Phase 3 topline results from ShORe, expected in mid-CY2025; BLA submission in 1H CY2026